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CONTROL OF VIRAL GASTROENTERITIS WITHIN JAILS AND PRISONS
OBJECTIVES
The learner will be able to describe the epidemiology,
transmission, symptoms, and signs of noroviruses.
The learner will be able to explain the most effective norovirus
infection control and containment methods.
The learner will be able to discuss useful ways to educate
inmates, health care professionals, and administrative staff on
the prevention and containment of noroviruses.
The purpose of this monograph is to
increase the knowledge of physi-
cians in correctional systems
regarding strategies for the preven-
tion, containment, and treatment of
noroviruses.
Purpose Statement
If you have any problems with this newsletter please call (401)453-2068 • fax (401)272-7562 or e-mail us at idcrme@gmail.com
Instructions for Credit
To obtain credit read the Main Article,
Table 1, Table 2, Table 3, and 101 sec-
tions of the monograph. When com-
pleted with these items, complete the
post test and evaluation on the last
page of the monograph. You must
receive a test score of at least 75% and
respond to all evaluation questions to
receive a certificate. Mail or fax the
post test and evaluation to:
IDCR
146 Clifford Street
Providence, RI 02903
or fax it to (401)272-7562
Main Article - Table 1:
Reported and estimated illnesses, frequency of food-borne
transmission, and hospitalizations for known food-borne
pathogens, United States- 2004
Main Article - Table 2:
The Kaplan Criteria for determining whether an outbreak of
gastroenteritis is of viral origin
Go to www.AAHIVM.org to learn about
membership, continuing education and
the new partnership with IDCR
101:
Preparation of Bleach Disinfectant Solutions
Joseph Bick, MD
Chief Deputy, Clinical Services
California Medical Facility,
California Department of Corrections
and Rehabilitation
Disclosures: Nothing to disclose
Introduction
The noroviruses are a group of related virus-
es in the Caliciviridae family. The name
“norovirus” comes from the first identified
member of this group, which was isolated
from diarrheal stools in 1972 during an out-
break of gastroenteritis in an elementary
school in Norwalk, Ohio. Subsequently,
noroviruses have been identified as the most
common cause of gastroenteritis in the U.S.
Noroviruses cause an estimated 23 million
cases of gastroenteritis each year in the U.S.,
more cases than are caused by all other viral,
bacterial, and parasitic agents combined.
Although noroviruses circulate year-round,
epidemics are most commonly recognized in
the winter and early spring.
Outbreaks of gastroenteritis due to norovirus-
es are especially common in congregate living
environments such as hospitals, long term
care facilities, military barracks, summer
camps, and cruise ships. More recently,
noroviruses have been identified as the cause
of gastroenteritis outbreaks in jails, prisons,
and detention facilities. Norovirus outbreaks
have the potential for significant morbidity,
occasional mortality, and disruption in the rou-
tine operation of correctional facilities. This
article provides recommendations to assist
medical and custody personnel in the diagno-
sis, treatment, and containment of gastroen-
teritis outbreaks in the correctional setting.
Epidemiology
There are approximately 267,000,000
episodes of diarrhea among adults in the U.S.
each year, resulting in an estimated 612,000
hospitalizations and 3,000 deaths.1 An etio-
logic agent is identified in less than 10% of
these cases of diarrhea, and most persons
with acute diarrhea do not seek medical care
as a result of their illness. The very young, the
elderly, and the immunocompromised are
most affected by these illnesses.
Little has been published on the frequency
and etiology of diarrheal illness among the
incarcerated. Inmates often store food in their
cells or dorms for later consumption, and do
not usually have access to refrigeration or
cooking appliances. Perishable food stuffs
can be a source of viral and bacterial gas-
troenteritis. In non-incarcerated institutional
settings, toxins and over 200 different bacte-
ria, viruses, fungi, and parasites have been
identified as the source of diarrheal outbreaks.
Contaminated foods that have been linked to
diarrheal illness include pork2, chicken3,
ground beef4, milk5, unpasteurized apple
cider6-7, spinach8, eggs9, raspberries10,
onions11, raw nuts12, cantaloupe13, toma-
toes14, soft cheeses15, and shellfish.16 Table
1 details the estimated total number of cases,
frequency of food-borne transmission, and
hospitalizations for the most common causes
of infectious organisms that can cause diar-
rhea in the U.S..
Signs and symptoms of noroviruses
The incubation period for norovirus following
infection is 12-48 hours. In healthy adults, clin-
ical signs and symptoms are generally mild
and of short duration, usually 12-60 hours.
The illness can be more severe in the elderly
and others who have compromised immunity.
Rarely, severe dehydration due to norovirus
can be fatal. There are no known long-term
sequelae that result from norovirus infection.
Most of those who become ill experience the
sudden onset of nausea, vomiting, abdominal
cramps, and diarrhea. Constitutional symp-
toms including low-grade fever, headache,
chills, and myalgias are common. Patients
may experience only vomiting, commonly
referred to as winter vomiting disease.17
Diarrhea due to norovirus is usually watery,
and less severe than that caused by bacteria.
After recovery from illness due to norovirus,
individuals generally experience short-lived
immunity from recurrent illness and are there-
fore susceptible to repeated infection and dis-
ease within 6 months.
Transmission
Viral gastroenteritis can be introduced into a
jail or prison by employees, visitors, volun-
teers, or inmates who are transferred into the
facility. Less frequently, the virus can enter a
facility in contaminated food or water.
Norovirus is excreted in the stool of infected
persons, and can be shed from those who do
not become clinically ill. Excretion of virus pre-
cedes clinical illness and can persist for more
than a week after symptoms resolve.18-20
Noroviruses are readily spread from person to
person, by fomites, and from contaminated
environmental surfaces. The major route of
transmission is person to person (fecal-oral)
via hands contaminated with feces or emesis.
Norovirus is characterized by both a low infec-
tious dose (<100 viral particles) and a high
attack rate among exposed persons.21 The
prolonged shedding of virus in the stool of
asymptomatic persons increases the likeli-
hood of transmission by infected food han-
dlers. Noroviruses can survive temperature
extremes from freezing to 140 F, and resists
killing by numerous disinfectants including rel-
atively high levels of chlorine.22
Diagnosis
The first and most important step in the diag-
nosis of gastroenteritis is to remain vigilant,
especially when norovirus is known to be cir-
culating in the outside community. Once viral
gastroenteritis is suspected, a rapid definitive
diagnosis of the causative agent will help
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Dear Correctional Colleagues,
Each year, over 30 million cases of infectious diarrhea are diagnosed in the United States. The
overwhelming majority of these illnesses are due to viral pathogens, of which noroviruses are the
most common. Gastroenteritis outbreaks due to noroviruses have been reported in numerous set-
tings, including schools, day care, restaurants, military barracks, and cruise ships. More recent-
ly, norovirus outbreaks have been diagnosed in correctional facilities.
Jails and prisons are perfect settings for the incubation and propagation of viral gastroenteritis. In
many ways, correctional facilities are functionally very similar to large cruise ships. Both house
hundreds if not thousands of transient residents and employees, and in both settings the resi-
dents utilize a common source for food, water, and laundry. Eating is the main recreational activ-
ity for both inmates and cruise ship passengers, and neither inmates nor cruise ship passengers
can depart their vessel at will.
One important difference complicating gastroenteritis outbreaks in the correctional setting is that
in most jails and prisons, inmates perform much of the essential work including culinary, house-
keeping, grounds keeping, painting, and building maintenance. When a contagious disease out-
break such as viral gastroenteritis hits a correctional institution, the sudden loss of large numbers
of critical workers can severely impact day-to-day operations. Clearly, a prompt and effective
infection control response to contagious disease outbreaks is essential for both public health and
institutional safety and security.
This month’s issue of IDCR provides useful information and recommendations regarding the diag-
nosis and management of viral gastroenteritis in a correctional setting. It is our hope that by
preparing in advance, you, our correctional colleagues, will be better prepared to respond if /when
your facility is impacted by a gastroenteritis outbreak. As always, we welcome your feedback on
this and every issue, and encourage your recommendations regarding future infectious diseases
topics of interest.
Sincerely,
Joseph Bick, MD
Health Care Manager
Chief Deputy, Clinical Services
California Medical Facility
California Department of Corrections and Rehabilitation
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guide strategies for infection control and con-
tainment. An outbreak should be suspected if
> 2 inmates and/or employees concurrently
develop nausea, vomiting, and diarrhea. The
coexistence of vomiting and diarrhea is a use-
ful clue to the presence of norovirus.
During a suspected outbreak, fresh stool
should be collected from six to twelve per-
sons. In addition to testing specimens for
norovirus, stool should be cultured for campy-
lobacter, salmonella, and shigella. If the stool
is bloody, it should also be tested for E. coli
0157:H7. Noroviruses cannot be cultured.
Options for diagnosis include direct visualiza-
tion of viruses by electron microscopy (EM),
enzyme-linked immunosorbent assays (EIA)
for detection of virus in stool, the serologic
detection of a fourfold increase of specific
antibodies in acute- and convalescent-phase
blood samples, and the use of reverse-tran-
scription polymerase reaction (RT-PCR).22-25
Because most adults have been infected with
norovirus at some point, the simple presence
of IgG antibody to norovirus is not useful in
terms of making a diagnosis. Serologic diag-
nosis, therefore, requires detecting either
virus-specific IgM antibodies or rising anti-
body titers in paired acute and convalescent
blood samples. The time lag involved in the
development of antibodies further limits the
usefulness of serological diagnosis. Currently
available EIAs are insufficiently sensitive and
specific to justify more widespread use at this
time. RT-PCR has significantly improved the
ability to rapidly and accurately diagnose
norovirus as the cause of gastroenteritis out-
breaks. Most state public health laboratories
can test stool, emesis, rectal swabs, and envi-
ronmental swabs for noroviruses utilizing RT-
PCR. Norovirus can be identified from stool
specimens taken between 2 and 7 days after
onset of symptoms. Once the presence of
norovirus has been confirmed within a facility,
additional cases can be diagnosed with suffi-
cient accuracy utilizing clinical criteria. One
such definition, the Kaplan criteria, is quite
specific for viral gastroenteritis (see Table
2).26
Treatment
There are no specific antiviral therapies for
norovirus, and in most cases, oral re-hydra-
tion is sufficient. Occasionally, anti-emetics,
intravenous fluids, and/or electrolyte replace-
ment therapy is necessary.
Infection control and containment
In the absence of prompt, thorough infection
control measures, norovirus can circulate
within an institution for an extended period of
time. Managing an institutional outbreak of
any contagious illness requires close collabo-
ration between medical and custody staff.
During an outbreak of gastroenteritis, move-
ment of inmates should be restricted as much
as possible. Even those who are not sympto-
matic may be incubating the virus, and can
spread the illness to others. Movement in and
out of the impacted housing units should be
limited. Viral gastroenteritis is more likely to
be spread in congregate settings. For this rea-
son, strong consideration should be given to
temporarily suspending indoor group activities
such as visitation, school, and religious ser-
vices. Inmates who are experiencing nausea
and/or vomiting should be confined to quar-
ters until they have been asymptomatic for at
least 48 hours. Likewise, employees who are
ill should be encouraged to stay away from
the worksite until they have been without
symptoms for at least 48 hours. Sick inmates
should be fed in their cell, dorm, or housing
unit.
If possible, well inmates should eat in groups
by unit. The placement of alcohol-based hand
cleansers at the beginning of feeding lines
should be considered. Dining areas should be
cleaned and then wiped with bleach solution
between seatings.
Local operating procedures (LOPs) should
facilitate the closing of dormitories, yards, or
entire facilities to incoming inmates during
outbreaks of gastroenteritis and other com-
municable infectious disease such as varicel-
la, tuberculosis, or scabies. Movement within
the institution should also be limited as much
as possible. This includes bed moves, visiting,
religious meetings, mental health groups, art
and music programs, hobby shop, and inmate
canteen. All non-essential inmate work should
be temporarily suspended. The only inmates
who should be allowed to work are those who
have been symptom free for at least 48 hours.
Food handlers should be monitored to ensure
that they perform frequent hand hygiene and
appropriately use gloves. LOPs should also
provide for the rapid screening and clearance
of critical inmate workers. Plans should be in
place to allow for the identification on short
notice of alternate workers for food handling,
laundry, and essential functions.
Housecleaning and hand hygiene
During outbreaks of gastroenteritis, employ-
ees and inmates should be regularly remind-
ed about the importance of frequent hand
washing. Routine housecleaning efforts
should be intensified, including the cleaning of
walls, floors, table tops, handrails, sinks, toi-
lets, and door knobs in day rooms, communal
restrooms, dining facilities, and showers. In
addition to environmental surfaces, medical
and custodial equipment such as blood pres-
sure cuffs, stethoscopes, and restraint gear
should be routinely sanitized. Rapid response
teams should be created to remove and disin-
fect spills of body fluids such as feces or
vomit, especially in common areas. The body
fluid should be removed, and the area disin-
fected by the application of a bleach solution
for a minimum of ten minutes. After ten min-
utes, the excess solution should be wiped up.
Mop buckets should be disinfected and mop
heads cleaned or discarded after each
episode of cleaning up a contaminated spill.
Mops and other cleaning materials that are
used for cleaning up spills should not be
reused for routine cleaning in other areas. All
mop heads should be changed and either
laundered or discarded at least once daily.
Housecleaners should utilize wear personal
protective equipment to include masks, dis-
posable gowns, and gloves.
Based upon studies of viral killing with other
related calciviruses, chlorine bleach is the
only disinfectant that is fully endorsed by the
CDC for use against norovirus (see 101).
Therefore, bleach-containing solutions should
be used for surface cleaning and mopping.
The solution should be mixed fresh each day
utilizing 1 cup of bleach to 3 gallons of water.
This disinfectant solution must be changed
frequently to prevent dirt and organic materi-
als from inactivating the activate disinfectants.
The 101 Section provides directions for mix-
ing bleach solutions. Unfortunately, bleach is
caustic and could potentially be used in an
assault. Additionally, bleach can be used to
change the color of inmate clothing and/or
alter personal appearance by dying hair. For
these reasons, it is important to work in
advance with custody to develop procedures
that allow for the safe use of bleach when it is
legitimately necessary.
Inmates and employees should be encour-
aged to frequently wash their hands with soap
and water, or an alcohol-based hand rub.
Healthy inmates should be allowed access to
the showers first, followed by those inmates
who are ill. Showers should be cleaned and
disinfected with bleach solution after being
used by sick inmates.
Education and communication
Educational efforts should be directed at
inmates, employees, visitors, volunteers, and
the public. The use of multiple teaching meth-
ods including handouts, overheads, in-house
cable television channels, and posters is
encouraged. Inmate peer educators can be a
valuable resource, as can inmate advisory
counsels, inmate family groups, and labor
unions. Educational materials should be pro-
vided in multiple languages, and be written to
accommodate those with low levels of litera-
cy. Daily briefings should be provided to key
medical and custody stakeholders. The public
information officer should be prepared to com-
municate with the media and the surrounding
community if called upon to do so.
Tracking the outbreak
Tracking of all individuals (inmates and
employees) greatly facilitates the manage-
ment of outbreaks of viral gastroenteritis and
other communicable conditions. Each day, a
list should be updated with essential informa-
tion to include at least the inmate name, num-
ber, housing, date symptoms began and
ended, date of confinement to quarters and
release, date specimens collected, and
results of specimens. This information should
be collated each day into a new updated
report that can be shared with key outbreak
managers (see Table 3). Each day, a nursing
team should conduct face-to-face evaluations
of any inmates who are experiencing symp-
toms consistent with gastroenteritis. This is to
include new cases and those who are con-
fined to quarters. Nursing staff should careful-
ly monitor these individuals, and rapidly bring
them to medical attention if they require addi-
tional medical intervention such as intra-
venous fluid replacement.
Conclusions
Outbreaks of gastroenteritis commonly occur
in congregate living environments such as
jails and prisons. Most of these outbreaks are
due to viruses, with noroviruses being the
most common etiology. Gastroenteritis out-
breaks can result in a large number of sick
inmates and employees, significant morbidity,
and major disruption to normal programming.
A coordinated response involving on-site
medical and custody staff, augmented as
needed by local, county, and state public
health resources, can be quite effective in mit-
igating the impacts of gastroenteritis out-
breaks. Jail and prison administrators would
be prudent to establish policies and proce-
dures in advance of these outbreaks to help
facilitate the best possible outcome.
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ORGANISM % FOOD-BORNEESTIMATED TOTAL CASES HOSPITALIZATION RATE
Source: Modified from Diagnosis and Management of Food-borne Illnesses: A Primer for Physicians and Other Health Care Professionals. MMWR 2004; 53 (No. RR-4)
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Table 1:
Reported and estimated illnesses, frequency of food-borne transmission, and hospitalizations for
known food-borne pathogens, United States- 2004
VIRUSES
Norwalk-like viruses
Rotavirus
Astrovirus
Hepatitis A
BACTERIA
Campylobacter spp
Salmonella, non-typhoidal
Shigella spp.
Clostridium perfringens
Yersinia enterocolitica
Escherichia coli O157:H7
PARASITES
Giardia lamblia
Cryptosporidium parvum
23,000,000
3,900,000
3,900,000
83,391
2,453,926
1,412,498
448,240
248,520
96,368
73,480
2,000,000
300,000
40
1
1
5
80
95
20
100
90
85
10
10
N/A
N/A
N/A
0.130
0.102
0.221
0.139
0.003
0.242
0.295
N/A
0.150
Table 2: The Kaplan Criteria for determining whether an outbreak of gastroenteritis is of viral origin
Stool cultures negative for bacterial pathogens
Mean (or median) duration of illness - 12-60 hours
Vomiting in greater than or equal to 50 percent of cases
Mean (or median) incubation period (if known) of 24-48 hours
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CDC’s Norovirus (Viral Gastroenteritis) Website
http://www.cdc.gov/ncidod/dvrd/revb/gastro/norovirus.htm
CDC’s Norovirus in Healthcare Facilities Fact Sheet
http://www.cdc.gov/ncidod/dhqp/id_norovirusFS.html
Norovirus Activity --- United States, 2006—2007
CDC. MMWR August 24, 2007; 56(33);842-46.
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5633a2.htm
Department of Health and Human Services 2007 Adult and Adolescent
Antiretroviral Treatment Guidelines
http://aidsinfo.nih.gov/Guidelines/Default.aspx?MenuItem=Guidelines
International AIDS Society-USA Panel
2006 Recommendations of the Treatment for Adult HIV Infection
http://jama.ama-assn.org/cgi/content/full/296/7/827
National HIV/AIDS Clinician’s Consultation Center
Warmline: National HIV Telephone Consultation Services
1-800-933-3413
PEPline: National Clincian’s Post-Exposure Prophylaxis Hotline
1-888-448-4911
Perinatal Hotline: National Perinatal HIV Consultation and Referral Services
1-888-448-8765
CDC’s Correctional Health Website
http://www.cdc.gov/correctionalhealth/
American Correctional Health Services Organization
http://www.achsa.org/index.cfm
American Academy of HIV Medicine
http://www.aahivm.org/
RESOURCES
Transmission electron micrograph of noroviruses. The bar = 50 nm
Source: F.P. Williams, U.S. EPA
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Sample Case Log of Residents and Staff with Acute Gastrointestinal Illness
Source: Recommendations for the Prevention and Control of Viral Gastroenteritis Outbreaks in California Long-Term Care Facilities (CDHS, October 2006).
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Preparation of Bleach Disinfectant Solutions
June 2008 Vol. 9, Issue 23 visit IDCR online at www.IDCRonline.org
Dilutions of standard (5.25%)
bleach prepared fresh for use
within 24 hours
Dilutions of standard (5.25%)
bleach prepared fresh for use
within 24 hours
Bleach/water
Preparation
Bleach/water
Preparation
1:100
2 1/2 tablespoons (1/6 cup)
bleach in a gallon of water
1:50
5 tablespoons (1/3 cup)
bleach in a gallon of water
1:50
5 tablespoons (1/3 cup)
bleach in a gallon of water
1:25
10 tablespoons (2/3 cup)
bleach in a gallon of water
1:10
25 tablespoon (1 2/3 cup)
bleach in a gallon of water
1:5
50 tablespoons (3 1/3 cup)
bleach in a gallon of water
Desired Chlorine Concentration
500 ppm (0.05%) 1000 ppm (0.1%) 1000 ppm (0.5%)
“Ultra” concentrations of bleach contain 6-7.35% hypochlorite and are not recommended to avoid producing higher than intended concentrations of
chlorine.
48-Week raltegravir Data Confirm Salvage Safety, Potency, and
Tolerability
Raltegravir (Isentress) is the first FDA approved medication in a new
class of HIV drugs called integrase inhibitors. raltegravir is approved for
use in combination with other agents in patients who have developed
resistance to other antiretroviral therapy.
The efficacy and safety of raltegravir is being evaluated in two ongoing
phase III, randomized, double-blind, placebo-controlled trials
(BENCHMRK 1 and 2). At entry, all patients were failing treatment and
demonstrated resistance to three classes of antiretroviral therapy. The 3
primary endpoints for both studies are changes in CD4 count from base-
line, percentage of participants with viral load reduction to <400
copies/ml, and percentage of participants with viral load reduction to <50
copies/ml.
Interim analyses at 16 and 24 weeks demonstrated that raltegravir pro-
duced superior efficacy compared with placebo in all 3 endpoints.
Approximately 75% of study participants experienced a decrease in HIV
viral load to <400, and approximately 60% reached a viral load of <50. On
average, CD4 counts increased by 80/mm3.
More recently, combined 48 week data from BENCHMRK 1 and 2 was
presented at the 15th Conference on Retroviruses and Opportunistic
Infections (CROI) (Cooper et al, poster #788). The 48 week data demon-
strated that the response rates exhibited at weeks 16 and 24 have been
maintained to 48 weeks. Encouragingly, this agent has shown benefit
even in a significant number of patients who have low CD4 counts, high-
ly resistant virus, and viral loads >100,000.
Of note, approximately 45% of patients who had no other active agents in
the optimized background therapy (as assessed by genotype and pheno-
type) maintained <50 copies/ml at 48 weeks. Although this response in
highly resistant patients is encouraging, every effort should still be made
to utilize raltegravir in combination with at least one other fully active
agent. raltegravir has been very well tolerated, on par with placebo.
Thusfar, treatment with raltegravir has not lead to cross resistance to
other approved antiretroviral agents.
Data was also presented at CROI regarding the substitution of raltegravir
for efuvirtide (Fuzeon) in patients who have an undetectable viral load.
(Harris et al, Abstr. 99). Although this study involved only 29 patients with
a maximal follow-up of only 4 months, all patients maintained an unde-
tectable HIV viral load. If confirmed by further data, this may provide a
useful option for those patients who are unwilling or unable to continue
with a Fuzeon based regimen.
Mascolini, Mark. 15th Conference on Retroviruses and Opportunistic
Infections, Boston, February 3-6 2008.
California Governor Requests $7 Billion for Prison Health Care
In 2001, a class action law suit was brought against the State of California
over the quality of medical care in the state's 33-prison system. The court
found that the care was a violation of the Eighth Amendment of the U.S.
Constitution, which forbids cruel and unusual punishment of the incarcer-
ated.
The state settled the suit in 2002, agreeing to a range of remedies that
would bring prison medical care in line with constitutional standards.
However, the court ruled that the state failed to comply with the settle-
ment, and therefore established a Receivership in June 2005. This
Receivership has full authority to manage medical care operations in the
prison system.
In his 2008/2009 budget, California Governor Arnold Schwarzenegger
has requested an additional $7 billion for building and upgrading prison
medical and mental health care facilities. Most of the $7 billion
Schwarzenegger is requesting would be borrowed. This request is in
addition to $7.4 billion in bonds voters approved last year to pay for prison
and jail construction, and comes at a time that California is wrestling with
a projected budget deficit of $16 billion.
"Medical facilities, when they exist at all, are in an abysmal state of disre-
pair. Basic medical equipment is often not available," CDCR Receiver
Clarke Kelso said in a strategic plan he released last month. "Indeed, it is
a misnomer to call the existing chaos a 'medical delivery system'—it is
more an act of desperation than a system."
Don Thompson. Associated Press Writer; San Jose Mercury News;
California Prison Health Care Receivership Corp,
http://www.cprinc.org/about.htm
Trials of NIH HIV Vaccine Candidate Scaled Down After Failure of
Merck Vaccine
In September 2007, Merck abruptly halted a large-scale clinical trial of its
candidate HIV vaccine after initial analysis suggested that the vaccine not
only failed to prevent HIV infection in participants or delay the virus’s pro-
gression to AIDS, but might have made some participants more suscep-
tible to HIV infection. Subsequently, the NIH has announced that it will
significantly scale down its trials of the PAVE-100 HIV vaccine from the
original proposal.
The vaccine candidate uses a combination of the cold virus adenovirus-5
and DNA in order to stimulate cells to produce proteins that will generate
an immune response against HIV. Merck researchers found that individ-
uals who had a high baseline immunity to adenovirus-5 were at an
increased risk of contracting HIV.
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82008 National Health Care for the
Homeless Conference and Policy
Symposium
Phoenix, AZ
Country: United States
June 11-14, 2008
Visit: http://www.nhchc.org/2008
conference/2008conference.html
Tuberculosis Intensive - Seattle
Seattle, WA
June 19-20, 2008
Visit: http://www.nationaltbcenter
.edu/training/tb_intensive.cfm
2008 Viral Hepatitis Health
Leadership Summit
Baltimore, MD
June 20, 2008
Visit: http://www.hepfi.org/
TB Nurse Case Management
Albuquerque, NM
July 22-23, 2008
Visit: http://www.heartlandntbc.org/
training.asp
XVII International AIDS
Conference (AIDS 2008)
Centro Banamex Convention and
Business Centre
M_xico City, M_xico
August 3-8, 2008
Visit: http://www.aids2008.org/
American Correctional
Association - 138th Congress
of Correction
New Orleans, Louisiana
August 8-13, 2008
Visit: http://www.aca.org/
conferences/summer08/home.asp
The 48th Annual ICAAC/IDSA
46th Annual Meeting
Washington, DC
October 25-28, 2008
Visit: http://www.icaacidsa2008.org/
Correctional Mental Health
Seminar
Las Vegas, NV
July 13-14, 2008
Visit: http://www.ncchc.org/education
/mental/index.html
National Conference on
Correctional Health Care
Chicago, IL
October 18-22, 2008
Visit: http://www.ncchc.org/education
/national2008.html
SAVE THE
DATES Anthony Fauci, director of NIH’s National Institute of Allergy and Infectious Diseases, has announced that future
trials of the candidate vaccine will not include anyone who has a high immunity to the cold adenovirus-5, so as
to minimize risk of HIV-infection to the trial’s participants. As part of the scale down, the trial will only include 2,000
participants from Africa and the U.S., a marked decrease from the original 8,500 planned participants. The trial
will require that male participants be circumcised, a practice that has recently been found to reduce risk of HIV-
infection in men.
The International AIDS Vaccine Initiative, however, has announced plans to withdraw from the planned trials.
The group had intended to enroll 1,000 African participants in the trial, but has stated that the new trial is “a safe-
ty unknown” given the general lack of “clear understanding of why” the Merck vaccine candidate failed. Similarly,
many researchers have questioned new HIV vaccine trials in the wake of the unanticipated failure of the Merck
vaccine.
Kaiser Daily HIV/AIDS Report. Trials of NIH HIV Vaccine Candidate Scaled Down After Failure of Merck. March
25, 2008. http://www.kaisernetwork.org/Daily_reports/rep_index.cfm?DR_ID=51109
HPV in Heterosexuals, Prevalence and Factors Associated with Anal Lesions Mediated by HPV in Men
with HIV/AIDS
Researchers at the University Hospital in Pemambuco, Brazil are investigating the relationship between human
papillomavirus and anal lesions in men who are HIV-positive. Such co-infections with HIV and HPV are relative-
ly widespread, as both are transmitted through sexual contact. Persons who are co-inected with these viruses
stand a greater likelihood of having premalignant and malignant anogenital lesions due to HIV’s compromising
effect on the immune system. While antiretroviral therapy has been effective in reducing the prevalence of oppor-
tunistic infections in persons infected with HIV, such treatment has had little effect in preventing anogenital
lesions.
In response to a lack of information in this field, researchers in northern Brazil developed a study population of
sixty HIV-positive men who, on average, had been living with HIV-infection for 6.8 years. Approximately 88% of
the men had been on highly active antiretroviral therapy for over six years. 43.3% of the study’s participants were
homosexual, while heterosexuals comprised 41.7% of the patients. The remaining 15.0% of the patients identi-
fied themselves as bisexual. Over 60% of all participants reported having had receptive anal intercourse, and all
participants submitted to a series of diagnostic tests for anogenital lesions.
Anal lesions were found in 16.7% of patients according to anal cytology, 35.0% according to anoscopy under col-
poscopic vision, and 23.3% according to anal biopsy. Over 85% of patients with abnormal histology were homo-
sexuals or bisexuals and 78.6% of patients with anal lesions reported having had 10 or more same-sex partners
during their lifetime. Interestingly, CD4 cell count, viral load, and use of antiretroviral therapy seemed to have lit-
tle impact on anal biopsy results.
The results of this study call in to question the use of anal cytology as the sole screening test for anal lesions.
Researchers suggest that the screening process also include anoscopy under colposcopic vision and biopsy as
a means of preventing and diagnosing anal lesions in men co-infected with HIV and HPV. While a large portion
of this study’s participants were homosexual or bisexual men, it is important to note that HIV/HPV co-infected het-
erosexual men with no reported history of receptive anal intercourse can also be at risk for anal cancer.
HPV in Heterosexuals. Prevalence and factors associated with anal lesions mediated by human papillomavirus
in men with HIV/AIDS. H R Lacerda and R R Barros. International Journal of STD & AIDS 2008;19:192-96.
Is Jail Screening Associated With a Decrease in Chlamydia Positivity among Females Seeking Health
Services at Community Clinics?
San Francisco, 1997-2004
San Francisco’s Jail Health Services has partnered with the Center for Disease Control and Prevention’s
Epidemic Intelligence Service in order to research how chlamydia screening and treatment programs in jails
would impact chlamydia positivity among females attending neighborhood medical clinics.
Although chlamydia can lead to long-term health problems in women, including infertility and pelvic inflammato-
ry disease, the infection is generally asymptomatic and can go undetected if a patient is not tested for it. Like
most sexually transmitted infections (STIs), chlamydia disproportionately infects both incarcerated persons and
ethnic and racial minorities. As such, programs to screen and treat adults entering jail for chlamydia might
decrease chlamydia positivity in the neighborhoods where a substantial number of persons in jail usually reside.
In order to determine the impact of chlamydia screenings in jail on neighborhoods in San Francisco, researchers
compared jail screening rates by neighborhood from 1997 to 2004 to chlamydia positivity in two neighborhood
health clinics. Approximately 45% of eligible males and 38% of eligible females entering jail during the eight year
evaluation period were tested for chlamydia, resulting in 6.1% positivity in males and 7.3% positivity among
females. Of those inmates who tested positive for chlamydia, an estimated 81% were known to have received
treatment for their infection. Testing for chlamydia was conducted at health Clinics O and S among females aged
15 to 25 years. Females tested at Clinic S were predominantly black and patients tended to reside in neighbor-
hoods with jail testing density. In contrast, only a small percent of females tested at Clinic O were black and from
neighborhoods with high jail testing density.
Chlamydia positivity at Clinic S decreased significantly over the evaluation period, from 16.1% in 1997 to 7.8%
in 2004. In contrast, positivity remained constant at 4.7% in patients at Clinic O.
These results demonstrate that chlamydia screening in jail can have a significant impact on chlamydia positivity
in the outside community. Moreover, chlamydia screening was widely accepted amongst persons entering jail
and the vast majority of those who tested positive were able to be treated, despite the short length of jail stays.
This study underscores both the feasibility and importance of STI screening in jail as incarceration represents an
important opportunity to test and treat at-risk populations.
Is Jail Screening Associated With a Decrease in Chlamydia Positivity among Females Seeking Health Services
at Community Clinics? – San Francisco, 1997-2004. Barry, P et al. Sexually Transmitted Diseases. 2008;35(12).
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Objectives:
The learner will be able to describe the epidemiology, transmission, symptoms, and signs of noroviruses.
The learner will be able to explain the most effective norovirus infection control and containment methods.
The learner will be able to discuss useful ways to educate inmates, health care professionals, and administrative staff on the prevention and
containment of noroviruses.
1. The major route of transmission for the noroviruses is person to
person (fecal-oral) via hands contaminated with feces or emesis.
True or False
2. Which of the following is NOT a useful serologic indicator of
acute norovirus infection:
A. The presence of IgG antibody to norovirus
B. The presence of virus-specific IgM antibodies
C. Rising antibody titers in paired acute and convalescent
blood samples
3. Which of the following may be useful to prevent further
transmission of the norovirus within a correctional institution
A. Temporarily suspending indoor group activities such as
visitation, school, and religious services
B. Increasing hand washing of inmates and employees
C. Encouraging employees who are ill to stay away from
the worksite until they have been without symptoms for
1 or 2 weeks
D. Both A and B
4. The use of bleach as a disinfectant should be discouraged
because it has not been shown to be useful in killing noroviruses.
True or False
5. According to Table 2 which of the following is NOT a criteria for
determining whether an outbreak of gastroenteritis is of viral origin
A. Mean or median of incubation period (if known) of
24-28 hours
B. Vomiting in less than 25% of cases
C. Stool cultures negative for bacterial pathogens
D. None of the above
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IDCR EVALUATION
5 Excellent 4 Very Good 3 Fair 2 Poor 1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5 4 3 2 1 5 4 3 2 1
In the News 5 4 3 2 1 5 4 3 2 1
Save the
Dates 5 4 3 2 1 5 4 3 2 1
2. Do you feel that IDCR helps you in your work?
Why or why not?
3. What future topics should IDCR address?
4. How can IDCR be made more useful to you?
5. Do you have specific comments on this issue?
